Particle.news
Download on the App Store
9 ARTICLES
·
4w ago

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion

The $340 million upfront payment strengthens Omeros’ cash position, with Novo targeting Phase 3 PNH trials after closing.

A view shows a Novo Nordisk sign outside their office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, July 14, 2025. REUTERS/Tom Little/File Photo
Image
Novo Nordisk has agreed to acquire the development and commercialisation rights to Omeros' former lead rare blood disease asset, zaltenibart, in a deal worth up to $2.1bn. Image credit: Kittyfly via ShutterStock.com.
Image

Overview

  • Novo gains exclusive global rights to develop and commercialize zaltenibart for rare blood and kidney diseases, with additional milestones and royalties possible.
  • Zaltenibart blocks MASP-3 to curb the alternative complement pathway, a different approach from current complement inhibitors on the market.
  • The companies expect the transaction to close in the fourth quarter of 2025, after which Novo plans to launch a global Phase 3 program in paroxysmal nocturnal hemoglobinuria.
  • Omeros retains certain preclinical MASP-3 assets unrelated to zaltenibart, including the option to pursue small‑molecule inhibitors under limited restrictions.
  • Omeros shares jumped more than 150% on the announcement, as investors also look to an FDA decision on the company’s separate drug narsoplimab due December 26, 2025.